Fosun Pharma's global ambition, by Wang Fangqing

Much like its parent company Fosun Group, China’s Fosun Pharma also likes to shop.

In 2013, it bought the Israeli medical device company Alma Lasers and a hospital in Guangdong province; In 2015, it bought the American biotech company Ambrx with other Chinese investors, and in 2016 it paid over $1.2 billion to buy the Indian Gland Pharma, a deal that is currently waiting for approvals from authorities in China, India and the US.

“We continue to look around the world, especially in the US and emerging markets, for targets that fit our blueprint for future development,” Fosun Pharma chairman Chen Qiyu told the Pharma Letter in an exclusive interview.